Raymond James Financial Inc. Invests $1.45 Million in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Raymond James Financial Inc. purchased a new stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 109,317 shares of the company's stock, valued at approximately $1,447,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. QRG Capital Management Inc. lifted its stake in shares of Takeda Pharmaceutical by 16.8% during the 4th quarter. QRG Capital Management Inc. now owns 329,644 shares of the company's stock worth $4,364,000 after buying an additional 47,490 shares during the last quarter. Versant Capital Management Inc acquired a new stake in Takeda Pharmaceutical during the fourth quarter worth approximately $26,000. Russell Investments Group Ltd. boosted its holdings in shares of Takeda Pharmaceutical by 48.6% during the fourth quarter. Russell Investments Group Ltd. now owns 45,324 shares of the company's stock worth $600,000 after acquiring an additional 14,831 shares during the period. US Bancorp DE grew its position in shares of Takeda Pharmaceutical by 21.2% in the fourth quarter. US Bancorp DE now owns 124,332 shares of the company's stock valued at $1,646,000 after purchasing an additional 21,744 shares during the last quarter. Finally, Blue Trust Inc. increased its stake in shares of Takeda Pharmaceutical by 27.0% during the fourth quarter. Blue Trust Inc. now owns 14,430 shares of the company's stock worth $205,000 after purchasing an additional 3,071 shares during the period. 9.17% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Performance

Shares of Takeda Pharmaceutical stock traded down $0.08 during trading on Wednesday, reaching $15.10. The company's stock had a trading volume of 1,355,722 shares, compared to its average volume of 1,873,382. Takeda Pharmaceutical Company Limited has a 52 week low of $12.58 and a 52 week high of $15.43. The firm has a market cap of $48.03 billion, a PE ratio of 37.69, a P/E/G ratio of 0.24 and a beta of 0.26. The business's 50-day moving average price is $14.88 and its 200-day moving average price is $13.98. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its earnings results on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. Equities analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.